Sodium glucose co-transporter-2 (SGLT-2 inhibitors) have gained significant ground in the field of therapeutics of type 2 diabetes mellitus (T2DM) \[[@cit0001]\]. Recently, Gonzalez-Ortiz *et al.* demonstrated that dapagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, is also effective in patients with metabolic syndrome (MetS), but without T2DM \[[@cit0002]\]. The researchers showed that dapagliflozin led to a significant improvement in the parameters of MetS, resulting in remission of MetS in 58.3% of all stratified participants \[[@cit0002]\]. This observation may reflect the multiple, pleiotropic effects of this novel drug class.

It is established that SGLT-2 inhibitors enhance ketogenesis via mediating the decrease in insulin secretion (due to glucosuria and subsequent decrease in blood glucose levels) and counter-regulatory increase in glucagon levels, while there is evidence of direct action of SGLT-2 inhibitors on pancreatic α-cells \[[@cit0003]\]. Modest, but sustained ketone body reabsorption may also contribute to increased ketone body levels in subjects treated with SGLT-2 inhibitors. Ketogenesis is associated with a substantial increase in lipolysis rates, with shifting from glucose to free fatty acids as an energy substrate \[[@cit0003]\]. Gonzalez-Ortiz *et al.* demonstrated that dapagliflozin treatment in the corresponding arm resulted in a significant decrease in triglyceride levels and insulin secretion, which provides evidence on the background pathophysiologic mechanism \[[@cit0002]\].

The "hepatic fatty acid drainage hypothesis" and its implications in MetS have been formulated by Berge *et al*. \[[@cit0004]\]. Stimulation of ketogenesis and subsequent free fatty acid drainage from the liver can relieve fatty acid pressure on the adipose tissue and the skeletal muscle, improving insulin sensitivity and glucose uptake, along with a decrease in adipose tissue and ectopic fat accumulation \[[@cit0004]\]. Experimental data evince that impaired β-oxidation is closely related to severe insulin resistance and *vice versa* \[[@cit0005]\], while ketogenesis arises as a crucial regulator of glucose metabolism and fatty liver disease \[[@cit0006]\].

Despite the fact that there are insufficient data concerning the implications of pharmacologically induced ketogenesis in MetS, previous data support the application of nutritional ketosis in patients with MetS \[[@cit0007]\]. Utilization of free fatty acids and generated ketones as an alternative fuel substrate results in significant improvement in the major components of MetS. Although it is difficult to quantify and compare the ketogenic effects of a nutritional model to those mediated by a drug class, we must admit that there are certain similarities at the pathophysiologic level.

Additional data suggest that enhanced ketogenesis mediated by SGLT-2 inhibitors is associated with cardioprotection and renoprotection \[[@cit0008]\]. Previous data also support that ketogenesis is in fact a compensatory mechanism to hyperglycemia, correlated with cardio- and reno-protection, along with decreased incidence rates of all-cause mortality \[[@cit0009]\]. Based on the established association between MetS, all-cause mortality and cardiovascular mortality \[[@cit0010], [@cit0011]\], it is deduced that SGLT-2 inhibitors provide a promising therapeutic perspective in patients with MetS, and thus, underlying pathophysiologic mechanisms should be highlighted.

It seems that there is a sensitive balance between ketogenesis and ketoacidosis, with the existence of several underlying pathophysiologic mechanisms, including the aforementioned, that could interpret the association between the administration of SGLT-2 inhibitors and the occurrence of diabetic ketoacidosis \[[@cit0012]\]. Physicians should apply extra caution when prescribing this novel class of drugs in patients with T2DM, although the true risk has yet to be elucidated in the real-world setting \[[@cit0013]\]. Data retrieved from the most recent meta-analysis of 8 randomized controlled trials involving 10,157 patients on an SGLT-2 inhibitor-based regimen depict negligible odds for ketoacidosis with the administration of this drug class \[[@cit0014]\].

However, according to the results obtained from the recently published meta-analysis of the three hallmark cardiovascular and renal outcome trials, namely the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients--Removing Excess Glucose (EMPA-REG OUTCOME) \[[@cit0015]\], the Canagliflozin Cardiovascular Assessment Study (CANVAS) \[[@cit0016]\] and the Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) \[[@cit0017]\], administration of an SGLT-2 inhibitor in patients with T2DM increase more than twofold the risk of diabetic ketoacidosis, despite the quite low event rates \[[@cit0018]\]. Cohort studies will shed light on those findings \[[@cit0013]\].

In conclusion, SGLT-2 inhibitors offer a great perspective for the treatment of subjects with MetS, with or without concomitant T2DM; thus, we should focus on the beneficial ketogenic effects of this drug class. Further clinical trials, similar to that conducted by Gonzalez-Ortiz *et al*., but with quantification of the ketogenic effect of the administered SGLT-2 inhibitor, along with precise correlation estimates with MetS components, mainly body weight, glycemic control, lipid profile and blood pressure, will elucidate this reasonable hypothesis.
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